Sign in

John Wobel

Managing Director and Senior Analyst at Citizens JMP

John Wobel is a Managing Director and Senior Analyst at Citizens JMP, specializing in equity research for small- and mid-cap biotechnology and healthcare companies. He actively covers firms such as Prelude Therapeutics and LegalZoom, providing institutional clients with actionable ratings and in-depth sector insights, though public performance metrics and TipRanks rankings for his coverage are not widely available. Wobel began his career in finance analysis and has held senior research roles at Citizens JMP since at least 2023, contributing analytical expertise in healthcare and adjacent growth sectors. He maintains professional securities credentials, including FINRA registration and relevant licenses required for senior research analysts at a registered broker-dealer.

John Wobel's questions to Crinetics Pharmaceuticals (CRNX) leadership

John Wobel's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q4 2024

Question

An analyst on behalf of John Wobel asked for the regulatory and commercial rationale behind using a novel, differentiated endpoint for the atumelnant Phase III CAH trial.

Answer

CEO R. Struthers explained that atumelnant's unique mechanism aims to make it the primary treatment for CAH, with glucocorticoids used only for replacement. Chief Medical and Development Officer Dana Pizzuti added that the proposed endpoint will capture both dimensions of the drug's effect—reducing androgens and allowing for lower glucocorticoid doses—which could support a differentiated indication.

Ask Fintool Equity Research AI